The wellness boom is real. It may not be the IPO price.
Listen to the audio version of this article (generated by artificial intelligence).
Oura will go public at the perfect cultural moment. This is exactly what makes an IPO dangerous.
The smart ring maker has secretly filed draft IPO paperwork with the Securities and Exchange Commission, according to CNBC. The company says it is on track to surpass 5 million paid members this quarter. Revenues have reportedly increased fourfold over the past two fiscal years. Oura was valued at $11 billion last October following a $900 million Series E round, and has raised more than $1.5 billion in total.
Those are the numbers of the beast. They also explain why this IPO already contains a lot of good news.
Wall Street has discovered wearable health. Wellness has become a conversation at the dinner table. People who used to brag about 80 hours a week now brag about Zone 2 cardio, magnesium glycinate, eight hours of sleep, and a morning readiness score.
This transformation is real. It may last for decades.
But buying the best private company after the market has already found the subject is still a dangerous way to make money.
Just ask Peloton.
Peloton’s warning: A vision of the future doesn’t make an IPO safe
Peloton understood the future early.
Fitness was moving into the home. Devices can become a social product. The bike can become a media platform. Exercise can become a habit.
Peloton was right about the culture. Investors have paid pandemic complications for this story. Then demand normalized, competitors caught up, and the world reopened.
This is Aura Danger in miniature.
Oura may be a great product. It may continue to grow. It may even become one of the defining consumer health brands of the decade. An IPO can still be a bad entry point.
At a private valuation of $11 billion, Oura is valued less as a hardware company and more as a platform. CEO Tom Hill told CNBC that the company is on track to achieve about $1 billion in sales in 2025 and could approach $2 billion in 2026. Even if it reaches the high end of the 2026 goal, the latest private valuation still points to roughly 5.5 times those future sales.
This could work if Oura proves it has high retention software economics. Although the math gets tougher if the S-1 shows premium hardware works with a subscription wrapper.
Devices are copied. Sensors are getting cheaper. Wellness fads are cool. The winner turns health obsessions into lasting habits, services, locations, devices, records, and healing episodes.
Oura has a strong point of measurement. It is possible that winners in the public market own the rest of the system.
Healthy prosperity is much greater than the Oura Ring
The idea of Oura is simple: a small device monitors your body all day and all night, then turns that stream of signals into advice.
This sounds like an episode story. The money trail is bigger.
People change what they spend on. More dollars go to health, energy, fitness, sleep, appearance, longevity, and self-driving. A premium gym membership can indicate more than just a nicer bag. Rotating one shoe can be more important than another suit. A lab panel, a running clock, a GLP-1 sponsorship, a recovery score, or a training plan can all become part of the way a person sees themselves.
Ora follows the money. It has:
- AI training paid for through Oura Advisor
- Transition to metabolic health through Veri and Dexcom partnership
- Health Panels launched with Quest Diagnostics, offering about 50 vital signs for $99 with in-app interpretation.
- He purchased medical records technology through Galen AI
- Invested in women’s health, cardiovascular risk, and wellness foundation.
That is the correct map.
The issue is ownership. How much economic growth can Oura hold when the same trend fuels gyms, shoes, watches, phones, labs, therapy platforms, and clinical data companies?
10 Healthy Stocks to Buy Instead of Oura Ring’s IPO
As it turns out, many of those better-positioned stocks have already gone public.
Life Time: The cleanest gaming lifestyle
Life time group (LTH) may be the most culturally important stock in this entire basket. Aura tracks the body. Lifetime gives the body a place to go.
The company operates premium sports country clubs centered around fitness and recovery, swimming pools, classes, childcare, co-working spaces, cafes, spas and social living.
For a certain type of buyer, the new status symbol is a body that works, a decent enough degree of sleep to share, a trainer, a sauna, a pickleball court, and a place to spend a Saturday morning without feeling like trash. This is the hot time of life.
- Sales: $3.1 billion | Quarterly growth: 11.7% | Operating margin: 16.9% | Forward P/E: ~19x
- Risks: Real estate, debt, consumer spending, execution at the premium gym
- The trend is an unusually clean fit. This is a top lifestyle choice.
Garmin: The best wearable works
Garmin (GRMN) is the cleanest overall stock you can wear. It wins through trust rather than fashion – runners, cyclists, hikers, divers, pilots, golfers and endurance athletes buy Garmin because the products work.
Fitness segment revenues rose 42% year over year in the first quarter of 2026.
- Sales: $7.5 billion | Quarterly growth: 14% | Operating margin: 26% | Profit margin: 23%
- Garmin is mature, profitable, and designed for committed users — not health tourists.
Hims & Hers has the working class
He whispered and hers (Health Information Management System (HIMS).) is a very different type of stock adjacent to Oura. Oura measures and pays. Hims sells the business.
The company has built a direct consumer health path across sexual health, dermatology, mental health, weight loss and GLP-1-related care. It also has a natural path into biomarkers, diagnostics and AI coaching, giving it a broader monetization surface than a wearable brand.
- Sales: $2.4 billion | Gross Margin: 57% | Price to Sales: 2.5x | Short interest: ~31% of the float
- Short interest tells you that the market sees both sides. Hims have more advantages than mature names – and more ways to get hurt.
Quest: Boring vital signs engine
Diagnostic Quest (DJX) Boring in a useful way.
Oura Health Panels are powered by Quest — but Quest is already doing that job on a much larger scale. It performs blood and vital signs tests for doctors, hospitals, employers and direct consumers. Oura is one of the front doors of this laboratory system. It’s not the entire building Questhealth.com’s direct-to-consumer revenue grew 20% in the first quarter, with partnership-based testing growing even faster.
- Sales: $11.3 billion | Quarterly growth: 9.2% | Operating margin: 14.6% | Forward P/E: ~16.7x
- Hand waving is more difficult than a blood procedure compared to the degree of preparation. DGX is the boring toll road behind shiny wearables.
Dexcom: Better play for sensor linked to Oura
Discom (DXCM) invested in and participates in Oura – combining glucose data with sleep, activity and recovery signals. It’s already profitable, already expanding, and already key to the continuous glucose monitoring market.
- Sales: $4.8 billion | Quarterly growth: 15% | Operating margin: 21.5% | Forward P/E: ~23x
- Risks: Reimbursement, competition, pricing, and the pace at which CGM expands beyond diabetes into mainstream metabolic health.
- If metabolic tracking becomes a regular consumption habit, Dexcom is one of the cleaner, general ways to practice the habit.
Google has just made Oura trading riskier
Earlier this month, Google announced the Fitbit Air — a screenless fitness tracker starting at $99.99, designed for 24/7 health monitoring, paired with Google Health Coach, a fitness, sleep, and wellness advisor powered by Gemini.
alphabet (Google) is a huge mature roof with healthy option. The Fitbit Air will barely drive revenue on its own. The bigger point: Google has Android, Fitbit, Gemini, the cloud infrastructure, and the consumer reach. If health wearables become a market for AI training, Google is competing on the software layer while Oura fights hardware margin pressure.
Oura might sell something better. Google may own the decision layer.
Apple: Best device fingerprint, toughest AI question
apple (Apple) belongs in this conversation whether Oura bulls like it or not. The Apple Watch is already on millions of wrists. The Health app is already on the iPhone. Apple owns the hardware, the trust, the privacy playing field, the payment relationship, and the developer ecosystem.
The caveat: Apple’s health coaching ambitions have lagged behind its devices. The AI layer is not ready yet. Apple can still win — and the win may arrive later and with less force than investors expect.
AAPL is a participant in the underlying trend. It is a slower and safer way to own the theme.
Tempus and Illumina: the brain of health and plumbing data
Tempus AI (Tim) and Illumina (Elmen) is the data stack within the circular inventory story.
Tempus is closer to oncology, clinical AI, and diagnostics than it is to consumer health.
- Sales: $1.4 billion | Quarterly growth: 36% | Gross Margin: 62% | Operating margin: negative Short interest: ~25%
- Speculative growth – higher upside, higher risk of drawdown
- If AI-driven health data platforms succeed, Tempus could be important. If investors tire of unprofitable health AI stories, they could quickly be punished.
Illumina is the name of the sequencing infrastructure, less attractive after years of accumulation, but still close to the base of biology as data.
- Sales: $4.4 billion | Operating margin: 20.6% | Profit margin: 19.4% | Forward P/E: ~25x
- If longevity, prevention, and cancer screening continue to expand, sequencing will continue to be part of the mechanism.
Deckers: Lifestyle Distributions
Decker (Deck), through Hoka, captures the easier-to-understand version of the trend. HOKA directly changes behavior towards walking, running and low-impact endurance training.
- Sales: $5.5 billion | Quarterly growth: 8.7% | Operating margin: 22.8% | Forward P/E: ~13.7x
- Profitable and true trend display; The dangers of the fashion cycle
This is the “touch the grass and buy better shoes” part of healthy trading.
Two cautionary tales: What not to buy during a wellness boom
Peloton (Button) and Lululemon (Lulu) are cautionary tales worth considering — and leaving off your shopping list.
Peloton is proving that trend accuracy can’t save a stock when valuation, hardware cycle, and demand assumptions break.
Lululemon proves that a wellness identity alone is a thin protection. The brand is still valuable. The stock could still be cheap. The growth story has lost its clean look, and Mirror has already shown how difficult it is to associate connected fitness with a clothing brand.
They deserve to know. Neither of them belong on the buy list.
Bottom line: Let someone else buy Oura Ring’s IPO
Aura is part of an undeniable boom. However, this alone only attracts investors so far.
This company is going public after the market already understands the story: sleep tracking, recovery, metabolic health, AI coaching, preventive care, and longevity. The product is great. The brand is strong. The growth is impressive.
The stock could remain a trap if investors pay the platform’s prices before the S-1 proves the platform’s economics.
I want to see a breakdown of revenue and hardware gross margin versus subscription gross margin. I want to see churn rate, paid member attachment rate, group retention, customer acquisition cost, replacement cycles, lab economics, CGMs, employer programs, and AI training.
Until then, I’ll let someone else buy in at IPO prices.
The best trade is to buy companies that can survive after the fad wears off.
Oura could be a great company. It may one day become a staple of health wearables, the kind of product people wear at night automatically while their phones charge.
That still says very little about whether the stock will be a good bargain on IPO day. It is possible for a great product to be released to the public at a bad price. In this market, the best way to take advantage of a healthy boom may be to skip the IPO and buy companies that already have the pieces that last.
Oura won’t be the last IPO to test your discipline this year.
The window is already closing on what I believe are the most important pre-IPO trades in a generation. Most investors will find out about it on the day of the IPO – exactly when the best opportunity has already passed.
I spent months mapping the ecosystem. I know which stocks I want to own before the headlines come out.
